On June 13, 2024, Hong Kong's innovative medicine sector led the market. On the panel, Baekje China Leading the rise, Asheng Pharmaceuticals - B and Hehuang Pharmaceuticals followed suit, and the Hong Kong stock innovative drug ETF (159567) market was hot, with an average daily turnover of 74.43 million yuan in the past five trading days.
Tianfeng Securities He said that the trend of China's innovative drugs going to sea is clear. In 2024, a number of overseas rights and interests will be authorized, and the forms will be more diversified. After more than ten years of accumulation and iterative upgrading in recent years, China's innovative drugs may usher in more yuan and higher quality development. In 2024, the task of new medical reform was announced. Previously, Beijing, Guangzhou Huangpu and other places issued policies to promote and encourage high-quality development of the biomedical industry, and further clearly improved the support for the application and payment of innovative drugs. The policies of many places reflect that local medical insurance bureaus and relevant departments are actively promoting the implementation and use of innovative drugs to promote the healthy development of the industry. In a word, under the dual effect of continuous improvement of the payment side and improvement of the competition pattern, the research and development investment of domestic innovative drugs is expected to obtain more generous returns.
Related products: Hong Kong stock innovative drug ETF (159567)
Massive information, accurate interpretation, all in Sina Finance APP
